VEGFA and laryngotracheoesophageal cleft: While FDA-approved VEGF inhibitors, such as bevacizumab, demonstrate efficacy in advanced LC, their clinical utility is constrained by several inherent limitations: (1) Development of resistance mediated by vascular mimicry or hypoxia adaptation (7).